• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Awaiting tax reform clarity, Pfizer delays potential M&A

August 1, 2017 By Sarah Faulkner

Pfizer(Reuters) – Pfizer‘s (NYSE:PFE) chief executive said on Tuesday he would prefer to wait for clarity on U.S. tax reform before engaging in any big deals in order to get a better understanding of any potential acquisition target’s value.

The largest U.S. drugmaker has been under increasing pressure from investors and Wall Street to pull off a large deal to help reignite growth.

That pressure may intensify after Pfizer’s second-quarter revenue missed Wall Street estimates on Tuesday due to a decline in sales of the blockbuster pneumonia vaccine Prevnar and generic competition for Pristiq for depression.

“There are short-term events in the marketplace, such as tax reform, that may change asset values. Any focus on (business development) is somewhat delayed by resolution of that,” CEO Ian Read told analysts.

“If it’s not done this year and there’s no clear path that you could take to the bank of (tax reform) being done early next year, then you move on … and we’ll adapt our strategy accordingly,” Read said separately in an interview with Reuters.

Read called for a territorial tax change to ensure more equality with overseas-based rivals on U.S. taxes.

For the latest quarter, strong sales of newer products Xeljanz for rheumatoid arthritis, breast cancer treatment Ibrance and blood clot preventer Eliquis, shared with Bristol-Myers Squibb (NYSE:BMY), handily outperformed analysts’ forecasts.

However, overall revenue fell to $12.9 billion from $13.15 billion, below analysts’ average estimate of $13.08 billion, according to Thomson Reuters I/B/E/S.

“These results show that Pfizer’s growth drivers are still insufficient to drive meaningful sales growth against the backdrop of generic erosion,” Berenberg analysts said.

The company expressed confidence in its drug pipeline. Read said it has 15 drugs with annual sales potential of over $1 billion that could win approval over the next five years.

It has high hopes for approvals of earlier use of Ibrance and the prostate cancer drug Xtandi that would boost sales. An Xtandi approval for non-metastatic prostate cancer, for example, would significantly expand the number of patients and duration of use.

Pfizer raised the midpoint of its full-year adjusted earnings forecast by 2 cents and now expects $2.54 to $2.60 per share. It maintained a revenue forecast of $52 billion to $54 billion, as Prevnar in Europe, Xtandi and Pfizer’s biosimilar of the arthritis drug Remicade have not performed up to company expectations. Excluding items, Pfizer earned 67 cents per share, beating the average analysts’ estimate by a cent.

Pfizer shares were down 6 cents at $33.10.

Material from Reuters was used in this report.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Featured, MassDevice Earnings Roundup, Mergers & Acquisitions, Pharmaceuticals, Wall Street Beat Tagged With: Bristol-Myers Squibb Co., Pfizer Inc.

IN CASE YOU MISSED IT

  • Abbott could pave new roads in diabetes management with dual sensor on the horizon
  • Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
  • Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump
  • Beta Bionics to pair iLet automated insulin delivery system with Abbott’s dual glucose-ketone sensor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS